Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma

Ayman Qasrawi; Ranjana Arora; Reshma Ramlal; Reinhold Munker; Gerhard C. Hildebrandt

doi:10.1002/ajh.25725

Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma

Ayman Qasrawi
, Ranjana Arora
, Reshma Ramlal
, Reinhold Munker
, Gerhard C. Hildebrandt

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	E89-E91
Journal	American Journal of Hematology
Volume	95
Issue number	4
DOIs	https://doi.org/10.1002/ajh.25725
State	Published - Apr 2020

Bibliographical note

Funding Information:
GCH reports equity ownership from Sangamo Bioscience, Celgene/Juno, Kite Pharmaceuticals, Novartis, Insys Therapeutics, AbbVie, GW Pharmaceuticals, Cardinal Health, Immunomedics, Endocyte, Clovis Oncology, Cellectis, Aetna, CVS Health, Celgene, Bluebird Bio, Bristol‐Myers Squibb/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, and Jazz Pharmaceuticals, consultancy from Pfizer, Kite Pharmaceuticals, Incyte, and Jazz Pharmaceuticals, research funding from Takeda, Jazz Pharmaceuticals, and Pharmacyclin, travel, accommodations, or expenses from Kite Pharmaceuticals, Incyte, Pfizer, Falk Foundation, Jazz Pharmaceuticals, and Astellas.

Funding

GCH reports equity ownership from Sangamo Bioscience, Celgene/Juno, Kite Pharmaceuticals, Novartis, Insys Therapeutics, AbbVie, GW Pharmaceuticals, Cardinal Health, Immunomedics, Endocyte, Clovis Oncology, Cellectis, Aetna, CVS Health, Celgene, Bluebird Bio, Bristol‐Myers Squibb/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, and Jazz Pharmaceuticals, consultancy from Pfizer, Kite Pharmaceuticals, Incyte, and Jazz Pharmaceuticals, research funding from Takeda, Jazz Pharmaceuticals, and Pharmacyclin, travel, accommodations, or expenses from Kite Pharmaceuticals, Incyte, Pfizer, Falk Foundation, Jazz Pharmaceuticals, and Astellas.

Funders
CRISPR Therapeutics
IDEXX Laboratories
Incyte
Medarex
Falk Foundation
Bristol-Myers Squibb
Pfizer
Astellas Pharma Inc.
Johnson and Johnson
Proctor and Gamble
Takeda Pharmaceuticals U.S.A.
Jazz Pharmaceuticals
CVS Health Foundation

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25725

Cite this

@article{b46e0242d4de4cc0b5f837c63194ae76,

title = "Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma",

author = "Ayman Qasrawi and Ranjana Arora and Reshma Ramlal and Reinhold Munker and Hildebrandt, \{Gerhard C.\}",

note = "Funding Information: GCH reports equity ownership from Sangamo Bioscience, Celgene/Juno, Kite Pharmaceuticals, Novartis, Insys Therapeutics, AbbVie, GW Pharmaceuticals, Cardinal Health, Immunomedics, Endocyte, Clovis Oncology, Cellectis, Aetna, CVS Health, Celgene, Bluebird Bio, Bristol‐Myers Squibb/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson \& Johnson, Pfizer, Procter \& Gamble, Vertex, and Jazz Pharmaceuticals, consultancy from Pfizer, Kite Pharmaceuticals, Incyte, and Jazz Pharmaceuticals, research funding from Takeda, Jazz Pharmaceuticals, and Pharmacyclin, travel, accommodations, or expenses from Kite Pharmaceuticals, Incyte, Pfizer, Falk Foundation, Jazz Pharmaceuticals, and Astellas. ",

year = "2020",

month = apr,

doi = "10.1002/ajh.25725",

language = "English",

volume = "95",

pages = "E89--E91",

number = "4",

}

Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. / Qasrawi, Ayman; Arora, Ranjana; Ramlal, Reshma et al.
In: American Journal of Hematology, Vol. 95, No. 4, 04.2020, p. E89-E91.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma

AU - Qasrawi, Ayman

AU - Arora, Ranjana

AU - Ramlal, Reshma

AU - Munker, Reinhold

AU - Hildebrandt, Gerhard C.

N1 - Funding Information: GCH reports equity ownership from Sangamo Bioscience, Celgene/Juno, Kite Pharmaceuticals, Novartis, Insys Therapeutics, AbbVie, GW Pharmaceuticals, Cardinal Health, Immunomedics, Endocyte, Clovis Oncology, Cellectis, Aetna, CVS Health, Celgene, Bluebird Bio, Bristol‐Myers Squibb/Medarex, Crispr Therapeutics, IDEXX Laboratories, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex, and Jazz Pharmaceuticals, consultancy from Pfizer, Kite Pharmaceuticals, Incyte, and Jazz Pharmaceuticals, research funding from Takeda, Jazz Pharmaceuticals, and Pharmacyclin, travel, accommodations, or expenses from Kite Pharmaceuticals, Incyte, Pfizer, Falk Foundation, Jazz Pharmaceuticals, and Astellas.

PY - 2020/4

Y1 - 2020/4

UR - https://www.scopus.com/pages/publications/85078671597

UR - https://www.scopus.com/pages/publications/85078671597#tab=citedBy

U2 - 10.1002/ajh.25725

DO - 10.1002/ajh.25725

M3 - Letter

C2 - 31919891

AN - SCOPUS:85078671597

SN - 0361-8609

VL - 95

SP - E89-E91

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 4

ER -

Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this